Stocks · US
EXEL
XNAS
Exelixis Inc
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E16.94x
P/B7.91x
P/S5.99x
EPS$3.47
ROE46.68%
ROA34.50%
Dividend yield0.00%
EV/EBITDA14.02x
Debt/Equity0.00
Free cash flow$1.2B
Returns and 52-week range
1W-0.55%
1M-1.15%
3M+3.96%
6M+32.60%
1Y+45.50%
YTD+33.85%
52W high$61.14
52W low$33.76
From 52W high-4.60%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Neurocrine Biosciences Inc | $14.7B | 20.78 | 3.97 | -6.51% |
| 트위스트 바이오사이언스 | $13.6B | — | 30.49 | +33.88% |
| Charles River Laboratories International, Inc. | $14.8B | — | 5.22 | +5.71% |
| Corcept Therapeutics Inc. | $13.2B | 242.09 | 18.69 | +7.12% |
| Solventum Corporation | $15.0B | 10.45 | 3.12 | -5.07% |
| Icon Plc | $13.0B | 38.45 | 6.71 | -1.92% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.